Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

08 September 2020: Clinical Research  

Serum-Soluble ST2 Is a Novel Biomarker for Evaluating Left Atrial Low-Voltage Zone in Paroxysmal Atrial Fibrillation

Zefeng Wang1ACDE, Liting Cheng1BCD, Junmeng Zhang1AD, Zhuo Liang1CD, Ruiqing Dong2B, Fei Hang1B, Xinlu Wang1B, Ziyu Wang1B, Yongquan Wu1AD*, Jie Du3ADE

DOI: 10.12659/MSM.926221

Med Sci Monit 2020; 26:e926221

0 Comments

Abstract

BACKGROUND: Paroxysmal atrial fibrillation (pAF) recurrence after radiofrequency catheter ablation (RFCA) is linked to low-voltage zone (LVZ). This study explored whether serum soluble ST2 (sST2) levels can predict the size of LVZs in patients with pAF.

MATERIAL AND METHODS: A total of 177 patients with pAF treated with RFCA were consecutively enrolled in this study. One hundred twenty-five patients (70.6%) with <20% LVZ were assigned to Group A, and 52 patients (29.4%) with a LVZ >20% were assigned to Group B. Levels of soluble ST2 (sST2), growth and differentiation factor (GDF-15) and tissue inhibitor of MMP1 (TIMP-1) were measured.

RESULTS: The sST2 levels were higher in Group B than in Group A (23.9±3.3 vs. 30.9±5.0 ng/mL, P<0.000). In multivariable logistic regression analysis, sST2 was the only independent parameter for predicting left atrial LVZ (odds ratio, 1.611 [1.379–1.882]; P<0.001). The cut-off value of sST2 obtained by receiver operating characteristic (ROC) analysis was 26.65 ng/mL for prediction of LVZ (sensitivity: 86.5%, specificity: 84.8%). The under-curve area was 0.895 (0.842–0.948) (P<0.001). At 12-month follow-up, patients with sST2 <26.65 ng/mL had more patients free from atrial arrhythmias compared to patients with sST2 >26.65 ng/mL (88.6% vs. 69.8%, P<0.01).

CONCLUSIONS: We demonstrated that sST2 levels are higher in pAF patients with LVZ >20% compared to those with a smaller LVZ. Also increased sST2 levels can serve as a novel predictor of AF recurrence rate in patients who have undergone RFCA.

Keywords: Atrial Fibrillation, Biological Markers, Catheter Ablation, Aged, Heart Atria, Interleukin-1 Receptor-Like 1 Protein, Middle Aged, Recurrence

Background

Radiofrequency catheter ablation (RFCA) has become first-line treatment for patients with paroxysmal atrial fibrillation (pAF) who are intolerant or refractory to antiarrhythmic medication [1]. AF recurrence is a major complication after RFCA.

AF is a critical marker for predicting circumferential pulmonary vein isolation (CPVI) outcome [2,3]. The DECAAF Study showed that the recurrence rate in patients with AF area >20% was approximately 47.1% [4]. Yamaguchi et al. also emphasized that the survival rate was significantly reduced in patients with low-voltage zone (LVZS) >20% [5].

Some studies have provided evidence that late gadolinium enhancement (LGE)-magnetic resonance imaging (MRI) can be used to evaluate left atrial (LA) fibrosis [6,7]. However, this method requires initial visualization using a volume-rendering tool in Corview (Marrek), which is crucial for assessment. Although MRI is an advanced technique, it is costly and not extensively practiced in the clinic. Bipolar voltage mapping with electrophysiology analysis is a good standard for accurate and reliable detection and quantification of AFs [8–10]. Stegmann et al. also used 20% as a boundary to evaluate the relationship between low-voltage area in LGE and LVZ in three-dimensional electroanatomic mapping [11]. However, measuring AF requires an invasive procedure. Thus, searching for a simplified clinical method is imperative. As a result, identifying new biomarkers has become an important goal.

Some studies have yielded meaningful results. A number of biomarkers have been implied to be associated with cardiac fibrosis. A study [12] evaluating the association between extracellular matrix regulatory factors and AF risk showed that increased tissue inhibitors of metalloproteinases (TIMP) levels were significantly associated with AF risk. Growth differentiation factor (GDF-15) is a tumor growth factor-β family member. Marin’s research concludes that GDF-15 is regarded as a useful biomarker for risk stratification in AF [13]. Serum soluble ST2 (sST2) is a family member of the interleukin-1 receptors. Ma et al. show that sST2 is probably an objective biomarker that can predict AF patients’ risk of emergency admission or heart failure (HF), and elevated sST2 concentration may be involved in progression of AF [14]. However, TIMP-1, GDF-15, and sST2 have not been investigated for evaluating LA LVZ in AF patients. In this study, we aimed to explore whether there is a positive relationship between LA LVZ and levels of TIMP-1, GDF-15, and sST2 in serum.

Material and Method

STUDY DESIGN AND POPULATION:

During the period between January 2018 and December 2018, a total of 183 consecutive patients with pAF who underwent RFCA in the Cardiology Department of Beijing Anzhen Hospital were enrolled in this trial (Figure 1).

This study was approved by the Medical Ethics Committee of Beijing Anzhen Hospital. All participants evaluated in this trial signed written informed consent.

INCLUSION AND EXCLUSION CRITERIA:

Patients aged 18 to 80 years with symptomatic pAF intolerant of or refractory to antiarrhythmic medication or who wanted to take RFCA were eligible. (Based on duration of AF, patients diagnosed with pAF were defined as having AF terminating spontaneously or onset lasting <7 days with intervention).

Patients who had any of the following were excluded: (a) LA appendage thrombosis; (b) abnormal cardiac structures disease (i.e. severe mitral, tricuspid, aortic malformation); (c) HF; (d) history of RFCA, cryoballoon ablation, and cardiac surgical procedures; (e) mental disease; (f) estimated glomerular filtration rate (eGFR) <30 mL/min; (g) septic shock; (h) advanced malignant tumor; (i) pregnancy; (j) cardiac tamponade or major hydropericardium; or (k) LA anteroposterior diameter >50 mm.

DATA COLLECTION:

Data on demographics including gender and age were collected from the hospital database. Blood samples for TIMP-1, GDF-15 and sST2 testing were collected from each participant in sodium citrate tubes 1 day prior to the operation when patients were in sinus rhythm, then centrifuged, and plasma was stored at −80°C. Baseline clinical characteristics of all participants, including body mass index (BMI); history of coronary heart disease (CHD); alanine transaminase, aspartate aminotransferase, eGFR, creatinin, uric acid, glucose (GLU), total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglyceride levels; LA anteroposterior (LAAP) diameter; and ejection fraction (EF) were collected from medical records and confirmed by study physicians.

VOLTAGE MAPPING AND RFCA:

Voltage mapping procedures were performed on patients under local anesthesia. Electrode placement, transseptal puncture and CPVI were performed for every participant according to standard protocols. Briefly, after performing bilateral femoral vein punctures to obtain access to the heart, two 6-F introducer sheathes (Input; Medtronic, Minneapolis, United States) were inserted into the left femoral vein and two guidewires for the long sheath were inserted into the right femoral vein. A 10-polar diagnostic catheter was then inserted into the coronary sinus (CS) using fluoroscopic guidance, and transseptal puncture was performed twice and two non-steerable long sheathes were placed into the LA. A mapping catheter (PentaRay®; Biosense Webster, Diamond Bar, California, United States) and an ST ablation catheter (Thermocool smarttouch®; Biosense Webster, Diamond Bar, California, United States) were inserted into the LA through non-steerable long sheathes, followed by voltage mapping conducted using PentaRay. Point-by-point CPVI was performed using irrigated ablation catheters (Thermocool Smarttouch; Biosense Webster, Diamond Bar, California, United States) in a power control mode at 35 W (irrigation flow 17 mL/min). RFCA was performed using Visitag (Carto, Biosense Webster) guidance with catheter stability (2.5 mm for 3 s) and contact force (CF; >3 g for 25% of time) settings. The ablation index (AI) had a target value of 500 for the anterior LA wall and 400 for the posterior wall. During the procedure, heparin was delivered to maintain an activated clotting time between 300 and 350 s.

PARTICIPANT GROUPING:

According to results from bipolar voltage mapping, areas were defined using different colors as follows: (1) normal substrate (purple): bipolar voltage >0.5 mV in contiguous areas; (2) LVZ (colorful): bipolar voltage <0.5 mV in contiguous areas (Figure 2). The area of LA LVZ was measured offline within each region separately using the Carto system and presented in cm2 (total area refers to the entire LA area except for the pulmonary veins and mitral valve) (Figure 2). Many studies show that after RFCA, the recurrence rate of patients with an LA LVZ >20% was approximately 47.1% [4,15,16]. Based on those findings, patients were divided into Group A (no LVZ or <20%) and Group B (LVZ >20%) after quantification of the LA LVZ was obtained using bipolar voltage mapping (Figure 3).

FOLLOW-UP AND CLINICAL OUTCOMES:

Outpatients were followed up through hospital visit at 3, 6, and 12 months postoperatively. During this follow-up period, patients’ vital signs were recorded and cardiac ultrasound and 24-hour Holter monitoring was performed. AF recurrence was defined as recorded episodes of AF, atrial flutter (AFL), or atrial tachycardia (AT) lasting for at least 30 s 3 months after CPVI.

PRIMARY OUTCOMES:

The effectiveness of serum levels of TIMP-1, GDF-15 and sST2 in predicting LVZ served as the primary outcomes in this study. TIMP-1, GDF-15, and sST2 levels were measured using enzyme-linked immunosorbent assay kits (bsk11022, bsk11045 and bsk11100; Bioss antibodies). The limit of detection for sST2 was 15 pg/mL, with a mean inter-assay coefficient of variation <9.0%. Technicians were blind to the baseline patient characteristics.

SECONDARY OUTCOME:

Recurrence and composite outcome events served as the secondary outcome in this study. Recurrence was defined as the rate of pAF and composite outcome events at 12-month follow-up. Composite outcome events included: 1) major adverse events during the procedure (cardiac perforation, hydropericardium, malignant arrhythmias, sudden cardiac death, atrial-esophageal fistula, and acute myocardial infarction); and 2) rehospitalization rate (caused by AF, HF, and/or other heart-related complications).

STATISTICAL ANALYSIS:

Data were analyzed using SPSS statistical software (IBM, Version 23) and R (version 3.6.3). Continuous variables with normal distribution are expressed as mean ± standard deviation (SD), and non-uniformly distributed variables are expressed as median (Q1, Q3). Comparisons of means between groups were analyzed using the independent sample t-test for normally distributed data and the Mann-Whitney U-test for non-uniformly distributed data. The χ2 test was used to compare categorical variables. Results are presented as either the relative or absolute change in the marker with a 95% CI or P value. P<0.03 was considered statistically significant in the primary outcomes, and P<0.02 was considered statistically significant in the secondary outcome.

Factors associated with low-voltage zone were tested by univariate and binary logistic regression analyses. Variables with P<0.1 in the univariate analysis were tested in the multivariate model. Results were expressed as the P value and odds ratio (OR) in confidence interval (CI) of 95%. Receiver operating characteristic (ROC) analysis was done to determine the cut-off value of sST2 to predict LVZ. Hosmer-Lemeshow χ2 test was used to assess model goodness-of-fit.

Results

BASELINE CLINICAL MATERIALS:

The study included 177 patients (male: 123, 69.5%) who underwent RFCA. According to reference standard of LA) LVZ, 125 patients were assigned to Group A (no LVZ or <20%), and 52 patients were assigned to Group B (LVZ >20%).

Patients with low-voltage area >20% were older (P<0.03) and had higher eGFR and EF (Table 1).

PRIMARY OUTCOMES:

Serum sST2 concentration was significantly lower in Group A than in Group B (23.9±3.3 vs. 30.9±5.0, P<0.000) (Table 2). However, there was no meaningful difference in serum TIMP-1 and GDF-15 levels between the groups (82.2±24.1 vs. 84.4±27.9; 3.0±0.1 vs. 3.0±0.1, P>0.05) (Table 2).

MULTIVARIATE RELATIONSHIPS OF LA LVZ:

Age, eGFR, GLU, EF, and sST2 were related to LA LVZ. In multivariable logistic regression analysis, sST2 was the only independent parameter for predicting LA LVZ (1.611 [1.379–1.882]; P<0.001) (Table 3).

ROC CURVE ANALYSIS TO DETERMINE PREDICTIVE VALUE OF SST2 FOR LA LVZ:

The cut-off value for sST2 obtained by ROC curve analysis was 26.65 ng/mL for prediction of LA LVZ (sensitivity: 86.5%, specificity: 84.8%). Area under the curve was 0.895 (0.842–0.948) (P<0.001, Figure 4). We also used Hosmer-Lemeshow χ2 test and confirmed that goodness-of-fit was acceptable (P=0.387).

EVALUATING ACCURACY OF SST2 FOR DIAGNOSIS LA LVZ:

Table 4 shows sST2 level in relation to diagnosis of LA LVZ. The number of true positives, false positives, false negatives and true negatives can be easily identified.

COMPARISON OF SECONDARY OUTCOME BETWEEN TWO GROUPS:

We also conducted a 12-month follow-up after the procedure to evaluate the prediction value of sST2 in secondary outcomes (recurrence and composite outcome events). Patients were divided into Group 1 (sST2 <26.65 ng/mL) and Group 2 (sST2 >26.65 ng/mL).

There were 101 patients (88.6%) in Group 1 and 44 patients (69.8%) in Group 2 that were free from atrial arrhythmias (P<0.010). In addition, six patients (5.3%) in Group 1 and five patients (7.9%) in Group 2 developed composite outcome events with no significant difference between them (P>0.010) (Table 5).

Discussion

LIMITATIONS:

This trial had a small sample size, and long-term AF recurrence rates were not analyzed, both of which compromise the strength of our findings. Atrial stunning usually occurs in patients with AF after cardioversion and the duration depends on the duration of AF, LAAP, and structural heart disease [25]. In this study, we enrolled pAF patients with LAAP <50 mm without structural heart disease. Atrial stunning may affect low-voltage area but we considered atrial stunning would not significantly affect it.

Conclusions

We demonstrated that sST2 levels are higher in patients with pAF with LVZ >20% compared to those with a smaller LVZ. We further demonstrated that increased sST2 levels can serve as a novel predictor of AF recurrence rate in patients who have undergone RFCA.

References

1. Okamatsu H, Okumura K, Strategy and outcome of catheter ablation for persistent atrial fibrillation-impact of progress in the mapping and ablation technologies: Circ J, 2017; 82(1); 2-9

2. Moteleb A, Zarif JK, Ali AN, Incidence of atrial fibrosis in non-valvular atrial fibrillation patients and its impact on recurrence after pulmonary vein antral isolation: J Atr Fibrillation, 2018; 11(1); 1773

3. Liu Y, Niu XH, Yin X, Elevated circulating fibrocytes is a marker of left atrial fibrosis and recurrence of persistent atrial fibrillation: J Am Heart Assoc, 2018; 7(6); e008083

4. Marrouche NF, Wilber D, Hindricks G, Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: The DECAAF study: JAMA, 2014; 311(5); 498-506

5. Yamaguchi T, Tsuchiya T, Fukui A, Impact of the extent of low-voltage zone on outcomes after voltage-based catheter ablation for persistent atrial fibrillation: J Cardiol, 2018; 72(5); 427-33

6. Chelu MG, King JB, Kholmovski EG, Atrial fibrosis by late gadolinium enhancement magnetic resonance imaging and catheter ablation of atrial fibrillation: 5-year follow-up data: J Am Heart Assoc, 2018; 7(23); e006313

7. Kheirkhahan M, Baher A, Goldooz M, Left atrial fibrosis progression detected by LGE-MRI after ablation of atrial fibrillation: Pacing Clin Electrophysiol, 2020; 43(4); 402-11

8. Seitz J, Bars C, Gitenay E, What is the relevance of low-voltage maps to the underlying atrial scar?: JACC Clin Electrophysiol, 2019; 5(11); 1278-79

9. Chen J, Arentz T, Cochet H: Europace, 2019; 21(10); 1484-93

10. Herczeg S, Walsh K, Keaney JJ, Quantitative assessment of left atrial scar using high-density voltage mapping and a novel automated voltage analysis tool: J Interv Card Electrophysiol, 2019 [Online ahead of print]

11. Stegmann C, Jahnke C, Paetsch I, Association of left ventricular late gadolinium enhancement with left atrial low voltage areas in patients with atrial fibrillation: Europace, 2018; 20(10); 1606-11

12. Marin F, Roldan V, Biomarkers: GDF-15 and risk stratification in atrial fibrillation: Nat Rev Cardiol, 2015; 12(1); 8-9

13. Okumura Y, Watanabe I, Nakai T, Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: Importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence: J Cardiovasc Electrophysiol, 2011; 22(9); 987-93

14. Ma X, Yuan H, Luan HX, Elevated soluble ST2 concentration may involve in the progression of atrial fibrillation: Clin Chim Acta, 2018; 480; 138-42

15. Nortamo S, Ukkola O, Lepojarvi S, Association of sST2 and hs-CRP levels with new-onset atrial fibrillation in coronary artery disease: Int J Cardiol, 2017; 248; 173-78

16. Parikh RH, Seliger SL, Christenson R, Soluble ST2 for prediction of heart failure and cardiovascular death in an elderly, community-dwelling population: J Am Heart Assoc, 2016; 5(8); e003188

17. Siebermair J, Suksaranjit P, McGann CJ, Atrial fibrosis in non-atrial fibrillation individuals and prediction of atrial fibrillation by use of late gadolinium enhancement magnetic resonance imaging: J Cardiovasc Electrophysiol, 2019; 30(4); 550-56

18. Oz A, Cinar T, Kizilto Guler C, Novel electrocardiography parameter for paroxysmal atrial fibrillation in acute ischaemic stroke patients: P wave peak time: Postgrad Med J, 2020 [Online ahead of print]

19. Shen MJ, Arora R, Jalife J, Atrial myopathy: JACC Basic Transl Sci, 2019; 4(5); 640-54

20. Broch K, Andreassen AK, Ueland T, Soluble ST2 reflects hemodynamic stress in non-ischemic heart failure: Int J Cardiol, 2015; 179; 378-84

21. Okar S, Kaypakli O, Sahin DY, Fibrosis marker soluble ST2 predicts atrial fibrillation recurrence after cryoballoon catheter ablation of nonvalvular paroxysmal atrial fibrillation: Korean Circ J, 2018; 48(10); 920-29

22. Bootcov MR, Bauskin AR, Valenzuela SM, MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily: Proc Natl Acad Sci USA, 1997; 94(21); 11514-19

23. Stanciu AE, Vatasescu RG, Stanciu MM, The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation: Cytokine, 2018; 103; 63-68

24. Hu XJ, Zhan R, Xu S, Growth differentiation factor 15 is associated with left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation: Clin Cardiol, 2018; 41(1); 34-38

25. Khan IA, Atrial stunning: basics and clinical considerations: Int J Cardiol, 2003; 92(2–3); 113-28

SARS-CoV-2/COVID-19

16 September 2022 : Review article  

Effects of Physiotherapy on Rehabilitation and Quality of Life in Patients Hospitalized for COVID-19: A Rev...

Med Sci Monit In Press; DOI: 10.12659/MSM.938141  

03 October 2022 : Clinical Research  

Effect of Vitamin D Concentration on Course of COVID-19

Med Sci Monit 2022; 28:e937741

In Press

30 Sep 2022 : Clinical Research  

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic ...

Med Sci Monit In Press; DOI: 10.12659/MSM.938091  

30 Sep 2022 : Review article  

A Review of the Biological Mechanisms of Dexmedetomidine for Postoperative Neurocognitive Disorders

Med Sci Monit In Press; DOI: 10.12659/MSM.937862  

29 Sep 2022 : Animal Research  

Effect of Antilogous Platelet-Rich Plasma on the Revascularization of Rabbit Prefabricated Flap

Med Sci Monit In Press; DOI: 10.12659/MSM.937718  

26 Sep 2022 : Clinical Research  

Distribution and Determinants of Plasma Homocysteine Levels in a Preconception Population: A Retrospective ...

Med Sci Monit In Press; DOI: 10.12659/MSM.937987  

Most Viewed Current Articles

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Nov 2020 : Review article  

Long-Term Respiratory and Neurological Sequelae of COVID-19

DOI :10.12659/MSM.928996

Med Sci Monit 2020; 26:e928996

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750